Society of Hematologic Oncology

Free SOHO Membership: www.sohoonline.org

 

Chronic Myeloid Leukemia
17:08

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

CML State of the Art 2019: 2nd Generation TKIs Improve Molecular Outcomes and Are Generally Safe, Generic Imatinib Works Well, TFR is a Reality

FEATURING Jorge Cortés
  • 20 views
  • November 18, 2019
15:28

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Therapeutic Innovations in CML: Reducing Toxicity w/ Optimized Frontline Dosing or Programmed Dose Reductions, New ABL1 TKI Asciminib Is Very Promising

FEATURING Michael Deininger
  • 7 views
  • November 18, 2019
18:37

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Impact of Depth and Duration of Response of TFR in CML: Current Recommendations Differ by the Depth of DMR to Consider TKI Discontinuation

FEATURING Delphine Rea
  • 5 views
  • November 18, 2019
12:22

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Impact of Comorbidities in Treatment Choice of CML: TKI Toxicities Need to Be Considered, Frontline Therapy Switching/Stopping Depends on Comorbidites, Vascular Risk Major Consideration

FEATURING Timothy P. Hughes
  • 96 views
  • November 18, 2019
  • 1
15:19

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

29 y/o Male w/ CML: Allograft vs. 3rd Line Therapy - Transplant Is Always Relevant, Ponatinib Raises Concerns in Long-term Use, Asciminib Safe & Active in MDR AML

FEATURING Michael J. Mauro
  • 9 views
  • November 18, 2019
08:01

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

CML-044 ENESTop 192-Weeks Results on Treatment-Free Remission in Chronic Phase CML After Stopping 2nd Line Nilotinib

FEATURING Timothy P. Hughes
  • 4 views
  • November 18, 2019
13:11

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Phase 1 CML-041 Results on Combination of Asciminib, a Novel and Specific BCRABL1 Inhibitor, Plus Imatinib in Previously Treated CML

FEATURING Moshe Talpaz
  • 8 views
  • November 18, 2019